Correction: Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis

Authors:

Abstract
"[The one-year and two-year OS rates were 80.4% and 50.9%, respectively, in RT group, compared to 62.2% and 34.1%, respectively, in Non-RT group.]" [The PFS data after PSM was incorrectly copied as OS data]. A correction has been made to the section [Results, Survival outcomes, Paragraph 3]: "[After PSM, significant improvements in PFS(Figure3C,12.7months vs 6.5months, HR= 0.47, 95%CI:0.39-0.56, p<0.001)]" The original version of this article has been updated.
Funding Information
  • National Natural Science Foundation of China
  • Chinese Society of Clinical Oncology